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Ulcerative colitis (UC) is an inflammatory bowel disease characterized by inflammation restricted to 
the large bowel mucosa. Up to one-quarter of patients with UC will eventually undergo total 
proctocolectomy.1 
Since the first description by Parks in 1978, ileal pouch-anal anastomosis (IPAA) has become the 
surgical procedure of choice for both UC refractory to medical therapy and in those who develop 
colonic dysplasia or cancer and familial adenomatous polyposis (FAP).2  
Since UC is primarily restricted to the large bowel, it was expected that IPAA will enable eradication of 
diseased and cure the UC. However, following the surgery up to 30% may develop chronic pouchitis.3 
Pouchitis is clinically characterised by symptoms that include increased stool frequency, 
haematochezia, abdominal cramping, urgency, tenesmus, incontinence, fever and extraintestinal 
manifestations. 
Pouchitis is a nonspecific inflammatory condition in the ileal pouch reservoir.4 The fact that pouchitis 
occurs more commonly in those who have a pouch for UC than for FAP suggests that both the immune 
system and its regulation have a role in the aetiology. Some evidence suggests that an abnormal 
mucosal immune response to altered microflora in the ileal pouch leads to inflammation.  
The diagnosis of pouchitis has no standard definition. The most commonly used criterion is the pouch 
disease activity index (PDAI). The PDAI is a composite score including clinical symptoms, endoscopic 
findings and histological findings. A score greater than 7 is required for a diagnosis of pouchitis. 
Differential diagnosis of pouchitis include pouch ischemia, pouch stenosis, impaired pouch emptying, 
infectious diarrhea such as cytomegalovirus or clostridium difficile, Crohn’s disease (CD) of the pouch, 
adhesions. 
Controversy remains about anal and vaginal fistulas in patients with a pouch and what they represent. It 
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is possible that some of these are due to CD, whereas others are caused by underlying pelvic sepsis, 
surgical complication or cryptoglandular sepsis distinct from CD.5 
Although the majority of patients with pouchitis respond favourably to antibiotic therapy, particularly 
in the initial stage of the disease, in the longer term, in many patients pouchitis becomes refractory to 
conventional antibiotic therapy. In practice, antibiotics are often needed to maintain symptomatic 
response and symptoms return on withdrawal.  
Chronic pouchitis has no standard definition, but is often defined as the need for antibiotics for greater 
than 4 weeks with evidence of pouchitis.6 Chronic pouchitis develops in approximately 5%-19% of 
patients who either become dependent on antibiotics for symptom relief or have symptoms refractory to 
conventional therapies.7  
Regarding primary prophylaxis of pouchitis, a low-carbohydrate, low-fibre, and high-protein diet is 
recommended at baseline. In a randomized trial of 40 consecutive patients who underwent IPAA were 
given either probiotic therapy with VSL#3, 1 packet (900 billion bacteria including Lactobacillus 
species, Bifidobacterium supplementation, Streptococcus salivarius supplementation, and 
Thermophilus supplementation) each day or placebo for 12 months after ileostomy closure. VSL#3 
reduced the incidence of acute pouchitis—only 10% of patients that received VSL#3 (2/20) developed 
pouchitis, while 40% of the placebo group (8/20) developed pouchitis (P < 0.05).8 
The first-line treatment of acute pouchitis is empirical with antibiotics. Ciprofloxacin and 
metronidazole are the most commonly used, often generating a rapid dramatic response after a 2- to 4-
week course (70% of remission), with rifaximin and tinidazole being alternative agents to try in 
combination. Long-term use of antibiotics is poorly effective in achieving clinical remission for those 
patients with chronic pouchitis, but may be useful at keeping symptoms under control.9 
Patients with antibiotic-refractory pouchitis may need to opt for salicylates, corticosteroids (i.e. 
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budesonide), immunosuppressive drugs (i.e. azathioprine), or anti-TNF biologics. 
Treatment of a recurrent episode of pouchitis should first be directed toward a repeat trial of antibiotics 
or a trial of combination antibiotic therapy. 
Patients who continue to have relapses of pouchitis despite antibiotics at least 3 times each year are 
considered to have a chronic antibiotic-dependent pouchitis. These patients often require rotating 
courses of antibiotics, and these patients should also be placed on maintenance therapy. 
A randomized controlled trial of 40 patients given 2 packets/day of VSL#3 (600 billion bacteria) or 
placebo showed that VSL#3 was able to prevent a relapse during the study follow-up period of 9 
months (15% of VSL#3 had relapse vs 100% placebo, P < 0.001).8 
Oral budesonide is used at 9 mg/day for 3 months, then 3–6 mg/day for maintenance. Steroid therapy 
with budesonide has been tried in multiple small studies with reported remission rates of 60%–75%. 
Another steroid, beclomethasone diproprionate, was tried in an open-label study of 10 patients for 8 
weeks, and 80% of patients achieved remission based on a total PDAI < 4.10  
Topical mesalazine has been given to patients with pouchitis with clinical and endoscopic 
improvement. 
Immunosuppression with immunomodulators such as azathioprine or 6-mercaptopurine has also been 
used by some providers, although little data exists regarding the use of immunomodulator monotherapy 
for pouchitis. 
Studies including small numbers of patients (often fewer than 20), and mostly retrospective in design 
have demonstrated that infliximab appears to have good clinical effectiveness in selected patients with 
pouchitis, achieving up to 80% short-term and around 50% long-term response. Some data suggest that 
potentially, in some patients started on anti-TNF medications for pouchitis, we may be delaying 
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inevitable surgery rather than having a meaningful impact on disease course.11 
In an open-label, prospective, single arm, multicentre study was evaluated the efficacy of granulocyte 
and monocyte apheresis in patients that had active pouchitis while on conventional medical therapy 
including corticosteroids, amino-salicylates and anti-TNF biologics in addition to antibiotics. Nearly 
half of the patients (46%) responded to the treatment, but without achieving complete remission.12 
In a case series of 5 patients receiving multiple faecal microbiota transplantation (range 1–7) via 
flexible sigmoidoscopy had symptom resolution in 80% (4/5) within 4 weeks, and 75% (3/4) of the 
responders remained in remission for 3 months.13 
Finally, case series about emerging role of vedolizumab or ustekinumab as a treatment option for 
chronic have been published.14,15 
In conclusion, treatment of chronic refractory pouchitis remains an unmet need of UC’ management. 
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